- CHDI joins Proteome to identify Huntington's disease biomarkers
Proteome Sciences and the CHDI Foundation agreed to work together to identify protein biomarkers for Huntington's disease. Proteome will create protein expression maps for cell lines with varying levels of a gene alteration associated with Huntington's. "Proteome Sciences' expertise in this domain will provide an additional layer of information to help us and the wider HD research community probe the pathological mechanisms involved in this devastating disorder," said CHDI Basic Research Director Jamshid Arjomand. GenomeWeb Daily News (free registration) (8/20)       | Federal Circuit Again Upholds Myriad's BRCA Gene Claims | | Isolated DNA is patent-eligible because it is a "non-naturally occurring composition of matter," so said an appellate court in determining once again, the validity of Myriad Genetics Inc.'s claim for its BRACAnalysis breast cancer gene test. Find out the details. |  |
| Health Care & Policy |  |  | | - Researchers initiate stem cell trial for autism
Researchers at Sutter Medical Center in Sacramento, Calif., are beginning a clinical trial to evaluate the efficacy of umbilical cord stem cells as a therapy for autism. The trial, which will involve 30 children from 2 to 7 years old, is the first of its kind cleared by the FDA, according to the lead researcher. Patient enrollment starts today. Bloomberg (8/21) - Study: Molecule can protect stem cells from aging process
Researchers have discovered a molecule that can help prion proteins protect mesenchymal stem cells from DNA damage linked to the normal aging process. Stem cells treated with the molecule produced higher numbers of new cells, which were found to be of higher quality and were able to quickly form into fat and bone cells and those that support blood vessels and tissue, according to the study published in the journal Stem Cells. New Scientist (8/17)  | Earn 2X rewards points on gasoline purchases with The Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, shipping
• 1X points on everything else
LEARN MORE AND APPLY |
  | Company & Financial News | | | | - Pharmacyclics gets $50M from Janssen for lymphoma drug trial
Janssen Biotech paid Pharmacyclics a $50 million milestone fee after a fifth patient was enrolled in a clinical study of non-Hodgkin lymphoma drug ibrutinib. The payment is related to a development and marketing agreement signed last year. "We formed this partnership with Janssen, with the intention to broadly expand and propel the clinical development of ibrutinib," Pharmacyclics CEO Bob Duggan said. Fox Business/Dow Jones Newswires (8/20) - Venture to focus on genetics, personalized therapies
The Phoenix-based International Genetics Consortium and the University of Michigan Health System have formed a joint venture called Paradigm to advance genetic research and personalized medicine. Paradigm will offer gene sequencing and molecular diagnostics for health care providers, as well as support for clinical studies. BeckersHospitalReview.com (8/20) | Global Developments | | | | - Ariad's leukemia drug ponatinib enters Phase I/II trial in Japan
Ariad Pharmaceuticals initiated a Phase I/II trial of ponatinib, an investigational drug for a rare form of leukemia, in Japan. The trial will enroll patients with chronic myeloid leukemia who don't respond to dasatinib or nilotinib or those with Philadelphia chromosome-positive acute lymphoblastic leukemia who failed to respond to tyrosine kinase inhibitors. Mass High Tech (Boston) (8/20)
| Food & Agriculture | | | | | Industrial & Environmental | | | | | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Some people like my advice so much that they frame it upon the wall instead of using it."
--Gordon R. Dickson,
American author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, August 20, 2012
- Friday, August 17, 2012
- Thursday, August 16, 2012
- Wednesday, August 15, 2012
- Tuesday, August 14, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment